MedChemExpress LLC (MCE)

MedChemExpress - Model UCL-TRO-1938 - 2919575-27-0

UCL-TRO-1938 is a potent small molecule allosteric activator of PI3Kα with an EC50 value of approximately 60 μM. UCL-TRO-1938 can induce cell proliferation and has cardioprotective effects from ischaemia reperfusion injury and enhances nerve regeneration following nerve crush[1][2][3][4][5].

UCL-TRO-1938

MCE China：UCL-TRO-1938

Brand：MedChemExpress (MCE)

Cat. No.HY-154848

CAS：2919575-27-0

Purity：99.98%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month

Shipping：Room temperature in continental US; may vary elsewhere.

Description：UCL-TRO-1938 is a potent small molecule allosteric activator of PI3Kα with an EC50 value of approximately 60 μM. UCL-TRO-1938 can induce cell proliferation and has cardioprotective effects from ischaemia reperfusion injury and enhances nerve regeneration following nerve crush.

In Vitro：UCL-TRO-1938 (0.01-100 μM, 24 h) induces cell proliferation and induces cell cycle progression in PI3Kα-WT MEFs[1]. UCL-TRO-1938 (1-30 μM, 40 min) induces PI3Kα signalling in a dose- and PI3Kα- dependent manner in rodent and human cells[1]. UCL-TRO-1938 promotes the phosphorylation of Akt S473 in the mimic group in TE-1 and ECA9706 cells[2].

In Vivo：UCL-TRO-1938 (10 mg/kg or 5 μM, 100 μM, i.v., a single dose 15 min prior to reperfusion or a single dose for 21 days) provides cardioprotection and stimulates nerve regeneration in model of ischaemia reperfusion injury in mice and rat sciatic nerve crush model of peripheral nerve injury and regeneration[1].

References：

[1]. Gong GQ, et al. A small-molecule PI3Kα activator for cardioprotection and neuroregeneration. Nature. 2023 Jun;618(7963):159-168. [Content Brief]

[2]. Shi H, et al. miR-30c-5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway. Thorac Cancer. 2024 Oct;15(30):2206-2216. [Content Brief]

[3]. Najam O. Exploring the role of cardiac mast cells in acute myocardial infarction and ischaemia-reperfusion injury[D]. UCL (University College London), 2023.

[4]. Kingwell K. PI3K activator taps route to regeneration. Nat Rev Drug Discov. 2023 Jul;22(7):537. [Content Brief]

[5]. Ni C, et al. An inappropriate decline in ribosome levels drives a diverse set of neurodevelopmental disorders. bioRxiv [Preprint]. 2024 Jan 9:2024.01.09.574708. [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。